摘要
目的:探讨地西他滨治疗低中危骨髓增生异常综合征(MDS)的疗效,分析患者生存预后因素。方法:回顾性研究47例在我院接受地西他滨治疗的低中危MDS患者治疗资料,地西他滨皮下注射20 mg/(m^2·d)×5 d,28 d为1个疗程。患者接受地西他滨治疗3-4个疗程后评价其治疗反应,分析生存预后因素。结果:根据修订的国际工作组标准(IWG),18例(38.3%)患者达到CR,13例(27.7%)患者达到PR,血液学改善7例(14.9%),7例(14.9%)死于肺部感染或骨髓抑制,2例转变为急性髓系白血病,中位生存时间为26个月。地西他滨方案治疗的整体有效率为80.9%(38/47)。患者的独立的不良预后因素为:IPSS分级高、MDS病程长、早期曾有MDS治疗、老年。结论:地西他滨治疗低中危MDS的长期疗效确切,治疗前的临床因素或许可以预测地西他滨治疗MDS的疗效结果。
Objective:To investigate the efficacy of decitabine in the treatment of patients with low-risk and moderaterisk myelodysplastic syndrome(MDS)and to analyze the prognostic factors.Methods:A retrospective study was conducted on 47 patients with low and moderate risk MDS treated with decitabine in our hospital.The course of treatment was 20 mg/(m^2·d)×5 d injected subcutaneously for 28 d as a course of treatment.After 3 to 4 courses of treatment,the therapeutic response and survival prognostic factors of patients were evaluated.Results:According to the revised IWG standard,18 patients(38.3%)achieved CR,13 patients(27.7%)achieved PR,7 patients(14.9%)showed hematological improvement,7 patients(14.9%)died of pulmonary infection or myelosuppression,2 patients transformed into acute myeloid leukemia.The median survival time of MDS patients was 26 months.The overall effective rate of decitabine regimen was 80.9%(38/47).The independent poor prognostic factors for survival were high IPSS grade,long course of MDS,early treatment for MDS,and elder.Conclusion:The long-term efficacy of decitabine in the treatment of low and moderate-risk MDS is definite.The clinical factors before treatment may predict the efficacy of decitabine in the treatment of MDS.
作者
舒华娥
方腾
SHU Hua-E;FANG Teng(Department of Hematology,The People's Hospital of Chongqing Kaizhou District,Chongqing 405400,China)
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2020年第1期214-217,共4页
Journal of Experimental Hematology
